GSK agreed to acquire Nuvalent for $10.6 billion, aiming to bolster its oncology pipeline with next-generation kinase inhibitors in NSCLC. The deal includes zidesamtinib (ROS1) and eladalkib (ALK), both with Breakthrough Therapy and Orphan Drug designations, plus an early-stage HER2 program. The acquisition follows a busy week for molecular-glue partnering, with Novartis also extending its collaboration with Orionis via a second deal that adds up to $1.4 billion and $40 million upfront. Together, the transactions underscore big pharma’s preference for assets with established clinical target engagement. For investors and R&D teams, the common thread is timing: FDA decision dates for Nuvalent’s programs are set later this year, meaning GSK’s portfolio expansion could translate into near-term catalysts if reviews go smoothly.